外周T细胞淋巴瘤研究进展：第57届美国血液学会年会报道

Research progress of peripheral T-cell lymphoma： reports from the 57th American Society of Hematology annual meeting

外周T细胞淋巴瘤（PTCL）约占所有非霍奇金淋巴瘤（NHL）的10％～15％，呈高度异质性且侵袭性强，容易出现耐药和疾病进展，目前尚无标准的治疗方案。第57届美国血液学会年会关于PTCL的报告涵盖了基础和临床多个方面。基础研究方面，新型ALK伙伴基因的发现进一步完善了ALK阳性间变性大细胞淋巴瘤（ALK＋ALCL）的发病机制。预后指标方面，免疫组织化学检测GATA3表达等为PTCL的预后监测提供了新的指标。治疗方面，belinostat联合CHOP、brentuximabvedotin联合CHP、罗米地辛联合ICE等新方案及移植的合理使用为PTCL患者的治疗提供了新方向，以alisertib、darinaparsin及denileukin diftitox等为代表的新型药物开展了初期临床试验，为trFCL的治疗提供了新希望。

Peripheral T-cell lymphoma （PTCL） accounting for 10 % to 15 % of non-Hodgkin lymphoma （NHL） is characterized highly heterogeneous and aggressive clinical course. PTCL patients are prone to suffer from chemotherapy refractory and disease progression. Reports on research progress of PTCL in the 57th American Society of Hematology annual meeting covered multiple respects of PTCL. In basic research, the novel partner genes further improve the pathogenesis mechanism of ALK＊ anaplastic large cell lymphoma （ALCL）. For prognostic indicators, GATA-3 expression detected by immunochemical assay provide a novel tool to monitor PTCL prognosis. Belinostat-CHOP, brentuximab vedotin-CHP, romidepsin-ICE regimens and stem cell transplantation provide more options for patients with PTCL, and the novel drugs such as alisertib, darinaparsin and denileukin diftitox offer new hope for PTCL patients in preclinical trials.